226 related articles for article (PubMed ID: 7863823)
1. Interactions of growth hormone and parathyroid hormone in renal phosphate, calcium, and calcitriol metabolism and bone remodeling in postmenopausal women.
Lieberman SA; Holloway L; Marcus R; Hoffman AR
J Bone Miner Res; 1994 Nov; 9(11):1723-8. PubMed ID: 7863823
[TBL] [Abstract][Full Text] [Related]
2. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
[TBL] [Abstract][Full Text] [Related]
3. Skeletal response to recombinant human growth hormone (rhGH) in children treated with long-term corticosteroids.
Sanchez CP; Goodman WG; Brandli D; Goldenhersh M; Murray C; Carlton E; Hahn T; Salusky IB
J Bone Miner Res; 1995 Jan; 10(1):2-6. PubMed ID: 7747627
[TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
5. Effects of estrogen on daylong circulating calcium, phosphorus, 1,25-dihydroxyvitamin D, and parathyroid hormone in postmenopausal women.
Packer E; Holloway L; Newhall K; Kanwar G; Butterfield G; Marcus R
J Bone Miner Res; 1990 Aug; 5(8):877-84. PubMed ID: 2173358
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term treatment with loop diuretics on bone mineral density, calcitropic hormones and bone turnover.
Rejnmark L; Vestergaard P; Heickendorff L; Andreasen F; Mosekilde L
J Intern Med; 2005 Feb; 257(2):176-84. PubMed ID: 15656876
[TBL] [Abstract][Full Text] [Related]
7. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers.
Brixen K; Nielsen HK; Mosekilde L; Flyvbjerg A
J Bone Miner Res; 1990 Jun; 5(6):609-18. PubMed ID: 2382586
[TBL] [Abstract][Full Text] [Related]
8. Effect of parathyroid hormone (hPTH[1-34]) infusion on serum 1,25-dihydroxyvitamin D and parathyroid hormone in normal women.
Kinyamu HK; Gallagher JC; Petranick KM; Ryschon KL
J Bone Miner Res; 1996 Oct; 11(10):1400-5. PubMed ID: 8889838
[TBL] [Abstract][Full Text] [Related]
9. Short-term treatment with growth hormone stimulates osteoblastic and osteoclastic activity in osteopenic postmenopausal women: a dose response study.
Brixen K; Kassem M; Nielsen HK; Loft AG; Flyvbjerg A; Mosekilde L
J Bone Miner Res; 1995 Dec; 10(12):1865-74. PubMed ID: 8619366
[TBL] [Abstract][Full Text] [Related]
10. The effects of menopause and age on calcitropic hormones: a cross-sectional study of 655 healthy women aged 35 to 90.
Prince RL; Dick I; Devine A; Price RI; Gutteridge DH; Kerr D; Criddle A; Garcia-Webb P; St John A
J Bone Miner Res; 1995 Jun; 10(6):835-42. PubMed ID: 7572305
[TBL] [Abstract][Full Text] [Related]
11. Effects of aluminum hydroxide on the parathyroid-vitamin D axis of postmenopausal women.
Villa ML; Packer E; Cheema M; Holloway L; Marcus R
J Clin Endocrinol Metab; 1991 Dec; 73(6):1256-61. PubMed ID: 1955506
[TBL] [Abstract][Full Text] [Related]
12. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
13. [Calcium-phosphate metabolism and bone markers in two patients with Noonan's syndrome treated with growth hormone].
Praticò G; Palano GM; Lo Presti D; Parisi G; Caruso-Nicoletti M
Minerva Pediatr; 2003 Dec; 55(6):593-8. PubMed ID: 14676730
[TBL] [Abstract][Full Text] [Related]
14. Effects of short term administration of recombinant human growth hormone to elderly people.
Marcus R; Butterfield G; Holloway L; Gilliland L; Baylink DJ; Hintz RL; Sherman BM
J Clin Endocrinol Metab; 1990 Feb; 70(2):519-27. PubMed ID: 2298863
[TBL] [Abstract][Full Text] [Related]
15. Permissive action of growth hormone on the renal response to dietary phosphorus deprivation.
Harbison MD; Gertner JM
J Clin Endocrinol Metab; 1990 Apr; 70(4):1035-40. PubMed ID: 2180972
[TBL] [Abstract][Full Text] [Related]
16. Parathyroid hormone (PTH)-related protein(1-36) is equipotent to PTH(1-34) in humans.
Everhart-Caye M; Inzucchi SE; Guinness-Henry J; Mitnick MA; Stewart AF
J Clin Endocrinol Metab; 1996 Jan; 81(1):199-208. PubMed ID: 8550752
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid hormone changes during phosphorus load in patients with chronic renal insufficiency with low serum parathyroid hormone or adynamic bone disease.
Cuppari L; Carvalho AB; Lobão RR; Martini LA; Cendoroglo M; Ventura RT; Draibe SA
Clin Nephrol; 2001 Jul; 56(1):35-43. PubMed ID: 11499657
[TBL] [Abstract][Full Text] [Related]
18. Gender variation in PTH sensitivity and rhythmicity following growth hormone replacement in adult growth hormone-deficient patients.
White HD; Ahmad AM; Syed AA; Clewes A; Peter R; Vora JP; Fraser WD
Clin Endocrinol (Oxf); 2004 Apr; 60(4):516-26. PubMed ID: 15049968
[TBL] [Abstract][Full Text] [Related]
19. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
[TBL] [Abstract][Full Text] [Related]
20. Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
Boyce RW; Paddock CL; Franks AF; Jankowsky ML; Eriksen EF
J Bone Miner Res; 1996 May; 11(5):600-13. PubMed ID: 9157775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
